Alzamend Neuro Inc.

08/04/2026 | Press release | Distributed by Public on 08/04/2026 19:51

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Hyperscale Data, Inc.
2. Date of Event Requiring Statement (Month/Day/Year)
07/29/2026
3. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc. [ALZN]
(Last) (First) (Middle)
11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 190
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
Director by deputization
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
LAS VEGAS, NV 89141
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Purchase Warrants 07/30/2021 07/30/2026 Common Stock 494 $4,050 I By Ault Lending, LLC(1)
Common Stock Purchase Warrants 04/26/2022 04/26/2027 Common Stock 988 $4,050 I By Ault Lending, LLC(1)
Common Stock Purchase Warrants 08/01/2024 08/01/2029 Common Stock 13,556 $108 I By Ault Lending, LLC(1)
Common Stock Purchase Warrants 09/27/2024 09/27/2029 Common Stock 8,667 $108 I By Ault Lending, LLC(1)
Common Stock Purchase Warrants 10/30/2024 10/30/2029 Common Stock 1,111 $108 I By Ault Lending, LLC(1)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Hyperscale Data, Inc.
11411 SOUTHERN HIGHLANDS PARKWAY
SUITE 190
LAS VEGAS, NV 89141
X Director by deputization

Signatures

/s/ Milton C. Ault, III, Executive Chairman 08/04/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Milton C. Ault, III, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

Remarks:
Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer. The holdings reported herein are separately disclosed on Section 16 filings made by Mr. Ault, and this filing is being made solely for the purpose of identifying HSD, ACG and Ault Lending directly as reporting persons for Section 16 purposes.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Alzamend Neuro Inc. published this content on August 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 05, 2026 at 01:52 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]